Company intelligence / Profile preview

Uniogen

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

Uniogen’s lead program focuses on early detection of ovarian cancer using a novel glycovariant immunoassay with enhanced sensitivity/specificity. The product family aims to address unmet needs in early-stage oncology diagnosis. No published clinical results yet; products are currently under development.

Therapeutic areas: OncologyInfectious Diseases
Modalities: ImmunoassayPCR-based diagnostics (molecular diagnostics)Nanoparticle-based diagnostics (Upcon™ labeling technology)Instrumentation for diagnostic assays
Industry: Molecular Diagnostics

Drug pipeline

2 assets

GLYVAR Ovarian

Pre-clinical

Indications: Ovarian cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Corporate US and European IVD customers via CDMO/OEM partnerships; no specific major pharma/biotech partners named publicly.

Beyond the preview

Go deeper on Uniogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uniogen.

Explore the full profile